Pharmatech, Inc. and Suzhou Pengxu Pharmatech Co. | Date: 2014-11-26
Crystalline Form I of ibrutinib, processes for its preparation, pharmaceutical compositions comprising the new Form, and use of Form I of ibrutinib for treating or delaying diseases or disorders related to activity of Brutons tyrosine kinase (BTK) proteins are disclosed. The novel Form was characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. It can be readily prepared and is suitable for use in the preparation of solid dosage forms.
Pharmatech, Inc. | Date: 2014-02-05
The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients.
Pharmatech, Inc. | Date: 2014-12-30
Methods, devices, and systems for treating a respiratory condition using gNO delivered from a nitric oxide releasing solution (NORS) are disclosed and described. In one embodiment, the respiratory condition may be bovine respiratory disease complex (BRDc).
Pharmatech, Inc. | Date: 2015-06-18
A tablet that rapidly disintegrates in the oral cavity comprising a compressed blend of rapidly dispersing microgranules prepared by granulating a sugar alcohol or a saccharide or a mixture thereof having an average particle size less than about 30 microns and a disintegrant, and a taste-masked microcapsule containing at least one drag, the microcapsule being prepared by granulating a pharmaceutically acceptable formulation comprising at least one drug in a therapeutically effective amount and at least one polymeric binder that improves resilience of the microgranules, wet milling the granulated mass, and microencapsulating the milled granules to provide microcapsules.
Pharmatech, Inc. | Date: 2015-03-11
Orally administered corticosteroid compositions and methods for treating a condition associated with inflammation of the gastrointestinal tract in an individual, comprising administering to an individual said orally administered corticosteroid composition are disclosed.
Pharmatech, Inc. | Date: 2014-07-29
This invention relates to an oral stabilized modified release pharmaceutical dosage form containing L-methylfolate calcium, which is primarily absorbed from proximal small intestine via a saturable human proton-coupled folate transporter (h-PCFT) mediated transport intended as monotherapy for the treatment of patients with MDDs and/or diagnosed with dysthymia, schizophrenia, or degenerative dementia of the Alzheimer type.
Pharmatech, Inc. | Date: 2015-08-18
Systems, compositions, devices, and methods for treating a mammary condition in a mammal using gNO delivered from a nitric oxide releasing solution (NORS) are disclosed and described. In one embodiment, the mammary condition may be mastitis.
Pharmatech, Inc. | Date: 2014-10-17
The present invention relates to a system and method of treating a subject with nitric oxide gas and/or nitric oxide releasing solutions. The present invention also relates to compositions and devices useful for treating a subject with nitric oxide gas and/or nitric oxide releasing solutions.
Pharmatech, Inc. | Date: 2015-11-20
Disclosed are sensitive methods for detecting a target substance in low concentrations. The method can include immobilizing a target substance to a solid phase; incubating the immobilized target substance with a reporter enzyme detection probe in solution under conditions for forming target: enzyme detection probe complexes; washing the solid phase to remove any unbound reporter enzyme detection probe; incubating the target: enzyme detection probe complex with a reporter enzyme detection probe substrate in substrate reaction solution to generate one or more ionizable products; and detecting one or more of the one or more ionizable products using mass spectrometry (MS).
Pharmatech, Inc. | Date: 2016-01-21
An animal intranasal administration device, and associated systems and methods, are disclosed. The animal intranasal administration device can include a nasal passage nozzle for each nostril configured to receive fluid from a fluid source. The animal intranasal administration device can also include a biasing mechanism to bias the nozzles toward a septum such that the device is secured in place about the septum during administration of the fluid into nasal passages.